Semma Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA



Total Funding



Estimated Revenue & Valuation

  • Semma Therapeutics's estimated annual revenue is currently $12.9M per year.(i)
  • Semma Therapeutics received $114.0M in venture funding in November 2017.
  • 0
  • Semma Therapeutics's total funding is $163M.

Employee Data

Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Semma Therapeutics is pioneering the new treatment paradigm of using cells as medicine. Semma's new class of regenerative medicine therapies couples its breakthrough stem cell technologies with proprietary delivery systems designed to protect cells from the immune system. Ongoing research at Semma Therapeutics is focused on combining these highly-differentiated active cells with a state-of-the-art device to provide a functional cure for patients with diabetes. Semma Therapeutics is working to bring new therapeutic options to the clinic and improve the lives of patients. The company is headquartered in Cambridge, MA, with operations in Providence, RI. For more information, visit



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Semma Therapeutics News

2022-04-20 - Cellular Encapsulation Market Top Companies, Future Trends ...

... Eli Lilly and Sigilon, Novo Nordisk, Semma Therapeutics, evotec, Living Cell Technologies Limited, Neurotech Pharmaceuticals, Inc.,...

2022-04-06 - Esteemed Harvard Researcher Heads to Vertex to Curate Diabetes ...

For Melton, joining Vertex is something of a homecoming. Earlier in his career, he co-founded diabetes-focused Semma Therapeutics, which was...

2022-04-06 - Doug Melton to reunite with his Semma collaborators at Vertex to ...

Doug Melton to reunite with his Semma collaborators at Vertex to develop 'curative cell therapies'. Kyle LaHucik. Associate Editor. A reunion is happening at...

2019-09-08 - Vertex Purchases Semma Therapeutics For $950 Million

Vertex Pharmaceuticals plans to lay out $950 million in cash to buy Semma Therapeutics, a biotech company pursuing treatments for type 1 ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Semma Therapeutics Funding

DateAmountRoundLead InvestorsReference
2015-03-25$44.0MUndisclosedMPM CapitalArticle
2017-03-23$UndisclosedUndisclosedJDRF T1D FundArticle
2017-11-30$114.0MUndisclosedEight Roads VenturesArticle